GlassScriptPhysician profile
Raza Mehdi
NPI 1902890296
$2,118.80
in general payments reported to CMS, 2019-2025
24 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $147 · 2021: $57.01 · 2022: $571 · 2023: $389 · 2024: $93.09 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.86 | 2019-2024 | |
| Merz North America, INC. | $392.78 | 2019-2022 | |
| Allergan, INC. | $303.53 | 2019-2022 | |
| Pfizer INC. | $288.24 | 2022-2023 | |
| Galderma Laboratories, L.P. | $216.57 | 2019-2021 | |
| Dermira, INC. | $41.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.09 | 2024-2025 | |
| Genzyme Corporation | $36.55 | 2025 | |
| Botanix Sb INC | $34.67 | 2025 | Sofdra |
| Amgen INC. | $33.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.64 | 2024 | Libtayo |
| Strata Skin Sciences, INC. | $26.64 | 2025 | Xtrac |
| Incyte Corporation | $25.74 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $24.20 | 2022 | |
| Vyne Pharmaceuticals INC. | $23.58 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $20.23 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.93 | 2019 | |
| Lnhc, INC | $19.21 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $18.95 | 2025 | Zoryve |
| Organogenesis INC. | $18.48 | 2024 | Cygnus Dual |
| Prugen, INC. Pharmaceuticals | $18.15 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.42 | 2024 | Nuzyra |
| Abiomed | $16.14 | 2020 | |
| Horizon Therapeutics Plc | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.